BRTX insider transaction filings
BioRestorative Therapies, Inc. — 21 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-10-20. Screen BRTX transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for BRTX between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — BioRestorative Therapies, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-10-20 | 4 | Silva Francisco — VP of Research and Development, Director | Grant/award (A): 11,719 @ $1.60 · Grant/award (A): 11,719 (derivative) @ $0 | EDGAR |
| 2025-10-20 | 4 | ALSTODT LANCE — President, CEO, COB, Director, 10% owner | Grant/award (A): 15,625 @ $1.60 · Grant/award (A): 11,719 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Rosa David A — Director | Grant/award (A): 52,632 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Williams Patrick F. — Director | Grant/award (A): 52,632 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Kukekov Nickolay V. — Director | Grant/award (A): 52,632 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Kristal Robert Eugene — Chief Financial Officer | Grant/award (A): 166,492 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | Silva Francisco — VP of Research and Development, Director | Grant/award (A): 768,979 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | ALSTODT LANCE — President, CEO, COB, Director | Grant/award (A): 791,885 (derivative) @ $0 | EDGAR |
| 2024-11-05 | 4 | Broadrick Dale — 10% owner | Sale (S): 1,112 @ $1.58 | EDGAR |
| 2024-04-10 | 4 | Silva Francisco — VP of Research and Development, Director | Purchase (P): 476 @ $1.13 · Purchase (P): 1,232 @ $1.17 · Purchase (P): 6,600 @ $1.25 | EDGAR |
| 2024-03-20 | 4 | Silva Francisco — VP of Research and Development, Director | Tax withholding (F): 17,193 @ $1.39 | EDGAR |
| 2024-03-20 | 4 | ALSTODT LANCE — President, CEO, COB, Director | Tax withholding (F): 17,633 @ $1.39 | EDGAR |
| 2024-02-15 | 4 | Rosa David A — Director | Grant/award (A): 79,646 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Williams Patrick F. — Director | Grant/award (A): 79,646 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Kukekov Nickolay V. — Director | Grant/award (A): 79,646 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Paccasassi Robert — VP, QA and Reg Compliance | Grant/award (A): 219,298 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Kristal Robert Eugene — Chief Financial Officer | Grant/award (A): 263,158 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | Silva Francisco — VP of Research and Development, Director, 10% owner | Grant/award (A): 394,737 (derivative) @ $0 | EDGAR |
| 2024-02-15 | 4 | ALSTODT LANCE — President, CEO, COB, Director, 10% owner | Grant/award (A): 438,596 (derivative) @ $0 | EDGAR |
| 2024-02-12 | 4 | Broadrick Dale — 10% owner | Purchase (P): 73,959 @ $1.25 · Purchase (P): 86,041 @ $1.32 | EDGAR |
| 2024-02-09 | 4 | Broadrick Dale — 10% owner | Purchase (P): 36,374 @ $1.38 · Purchase (P): 83,626 @ $1.34 | EDGAR |
Recent 8-K events — BioRestorative Therapies, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-10 | 8-K/A | 4.01 — Changes in Registrant's Certifying Accountant 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-02 | 8-K | 4.01 — Changes in Registrant's Certifying Accountant 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-02 | 8-K | 3.03 — Material Modification to Rights of Security Holders 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-25 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-14 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-16 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 1.01 — Entry into a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-12 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-29 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=BRTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →